Business Context and Reporting Period
Company: Boston Scientific Corporation (BSX)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended September 30, 2025
Business Overview: A global developer, manufacturer, and marketer of medical devices used in interventional medical specialties, organized into two reportable segments: MedSurg and Cardiovascular.
Key Financial Metrics
| Metric (in millions) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Sales | $5,065 | $4,209 | $14,788 | $12,186 |
| Gross Profit | $3,542 | $2,897 | $10,175 | $8,395 |
| Gross Margin | 69.9% | 68.8% | 68.8% | 68.9% |
| Operating Income | $1,048 | $733 | $2,788 | $1,928 |
| Net Income (Attributable to BSX) | $755 | $469 | $2,226 | $1,288 |
| Diluted EPS | $0.51 | $0.32 | $1.49 | $0.87 |
| Operating Cash Flow (9M) | $3,170 | $1,979 | $3,170 | $1,979 |
| Total Debt | $11,600 | $10,746 | $11,600 | $10,746 |
| Cash & Equivalents | $1,275 | $2,502 | $1,275 | $2,502 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 20.3% in Q3 2025 and 21.4% for the nine months ended September 30, 2025, compared to the prior year. Growth was driven by organic sales (15.3% in Q3, 16.9% in 9M) and acquisitions (Silk Road Medical, Axonics, Intera, Bolt Medical, SoniVie).
- Profitability: Operating income rose 43% in Q3 and 45% in the 9M period. Adjusted net income (non-GAAP) was $1.124 billion ($0.75/share) for Q3 and $3.372 billion ($2.26/share) for the 9M period.
- Acquisitions: Significant M&A activity in 2025 included Bolt Medical ($475M), SoniVie ($362M), Cortex ($239M), Intera ($172M), and Anrei Medical ($182M). These contributed to goodwill increases and higher amortization expenses.
- Impairments: Intangible asset impairment charges were $46 million for the 9M 2025 period, a significant decrease from $276 million in the same period in 2024 (which included charges related to Cryterion and Devoro).
- Debt Structure: Issued €1.5 billion in Eurobonds in February 2025 to refinance maturing debt and fund general corporate purposes. Total debt increased to $11.6 billion.
Guidance, Outlook, and Risks
- Outlook: Management expects strong commercial execution to continue, particularly in Electrophysiology (Farapulse system) and Watchman (LAAC devices). Emerging Markets grew 11.8% in Q3.
- Restructuring: The 2023 Restructuring Plan was expanded by up to $250 million in July 2025 to drive operational efficiencies. Total estimated charges for the plan are now $700–$800 million. Activities are expected to be substantially complete by end of 2025.
- Product Discontinuation: Worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems were discontinued in May 2025, resulting in approximately $90 million in pre-tax charges.
- Legal & Regulatory: Ongoing litigation includes patent disputes (e.g., University of Texas System regarding Synergy Stent) and product liability claims related to transvaginal surgical mesh. The company is also subject to governmental investigations regarding FCPA violations in Vietnam.
- Tax Environment: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 includes changes to R&D expensing and international taxation, though management expects an immaterial impact in 2025.
- Future Acquisitions: Announced a definitive agreement to acquire Nalu Medical for approximately $533 million upfront, expected to close in H1 2026.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and integration progress of recent acquisitions (Bolt, SoniVie, Intera, Silk Road, Axonics) against management's growth targets.
- Restructuring Execution: Monitor the actual costs incurred versus the $700–$800 million estimated range for the expanded 2023 Restructuring Plan.
- Legal Accruals: Review the $306 million legal reserve balance and potential exposure from ongoing mesh litigation and patent disputes.
- Debt Covenants: Confirm continued compliance with the 2021 Revolving Credit Facility leverage ratio (currently 2.02x vs. 4.75x limit).
- Product Mix: Assess the impact of the ACURATE platform discontinuation on long-term Cardiology segment margins and the ramp-up of the Farapulse system.